Go Pro
OTCMKTS:IDXG

Interpace Biosciences Q1 2026 Earnings Report

Interpace Biosciences logo
$6.39 0.00 (0.00%)
As of 09/30/2026 02:15 PM Eastern

Interpace Biosciences EPS Results

Actual EPS
$0.15
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Interpace Biosciences Revenue Results

Actual Revenue
$9.03 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Interpace Biosciences Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Tuesday, May 12, 2026
Conference Call Time
7:00AM ET

Interpace Biosciences Earnings Headlines

Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Major Insider Move Signals Growing Confidence in PIMCO Dynamic
Borsa Istanbul Halts TNZTP.E for Short Circuit-Breaker Auction
See More Interpace Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Interpace Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Interpace Biosciences and other key companies, straight to your email.

About Interpace Biosciences

Interpace Biosciences (OTCMKTS:IDXG) is a molecular diagnostics company focused on providing testing and pathology services that support the diagnosis and management of cancer and other complex diseases. The company’s tests are designed to help physicians assess disease risk, improve diagnostic confidence and guide treatment decisions.

Its portfolio has included molecular tests for thyroid nodules, pancreatic cysts and gastrointestinal conditions. Key offerings include ThyGeNEXT and ThyraMIR for evaluating thyroid nodules, as well as PancraGEN and PanDNA for assessing pancreatic cysts. These products combine molecular analysis with clinical and pathology information to help distinguish potentially serious disease from conditions that may be monitored more conservatively.

Interpace serves physicians, hospitals, laboratories and other health-care providers primarily in the United States through its laboratory and commercial operations. The company previously operated under the PDI name before adopting the Interpace Biosciences identity as its business became centered on molecular diagnostics and personalized medicine.

View Interpace Biosciences Profile